RGNX
REGENXBIO Inc.
$6.08
-11.63%
$355.7M
No data for this timeframe.
Vol
Market Cap$355.7M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (89%)
Inst. Holders8 funds
Inst. Value$99.3M
Inst. Activity1 buys / 1 sells
Insider Activity0B / 2S
Insider Net $-$221.7K
SEC Reports3
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·CIK 0001590877·Prev Close $6.88
Recent Activity
Jun 5, 2026
short_volume
Short Volume: RGNX — 59.6% short (0.4M / 0.7M)
Short: 388,925 | Exempt: 7,720 | TRF Vol: 652,401 | Short Ratio: 59.6% | Off-exchange volume (dark p
Jun 3, 2026
SEC
REGENXBIO reported results of its 2026 Annual Meeting held May 29, 2026, where shareholders elected three Class II direc
8-K — Impact 3/10
May 29, 2026
Insider
Tasse Daniel sold 46,600 shares
Director @ $0.00 ($0.00)
May 29, 2026
Insider
STUMP DAVID C sold 46,600 shares
Director @ $0.00 ($0.00)
May 29, 2026
Insider
STUMP DAVID C sold 9,807 shares
Director @ $0.00 ($0.00)
May 14, 2026
SEC
REGENXBIO reported Q1 2026 results with a net loss of $90.1M ($1.72/share) vs. net income of $6.1M a year ago, as revenu
8-K — Impact 7/10
Mar 5, 2026
SEC
REGENXBIO reported financial results for Q4 and full year 2025, showing increased revenue driven by collaboration income
8-K — Impact 6/10
Inst.
BANK OF AMERICA CORP — TRIM
300,609 shares ($4.3M)
Price Targets
$24.18
+297.7% upside
Strong Buy
Current $6.08
Low $10.00
Median $19.00
High $50.00
11 analysts
$10.00
$50.00
Analyst Ratings
6Strong Buy
11Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 5, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| May 15, 2026 | B of A Securities | MAINTAIN | Buy → Buy |
| May 15, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| Mar 9, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 6, 2026 | Morgan Stanley | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.34 ▲ +244.3% | $0.10 — $0.73 | 125% YoY | 6 |
| Next Q | $-1.48 ▼ -33.0% | $-1.63 — $-1.39 | -23% YoY | 6 |
| Current FY | $-2.85 ▼ -42.5% | $-4.91 — $1.61 | 24% YoY | 8 |
| Next FY | $-2.52 ▼ -14.8% | $-4.58 — $-0.24 | 12% YoY | 6 |
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $48.6M | — |
| MORGAN STANLEY | $29.0M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $5.6M | NEW |
| RENAISSANCE TECHNOLOGIES LLC | $4.8M | TRIM |
| BANK OF AMERICA CORP | $4.3M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 29, 2026 | Tasse Daniel | A | $0.00 |
| May 29, 2026 | STUMP DAVID | A | $0.00 |
| May 29, 2026 | STUMP DAVID | A | $0.00 |
| May 29, 2026 | Zachary Jennifer | A | $0.00 |
| May 29, 2026 | Zachary Jennifer | A | $0.00 |
8 institutional holders with $99.3M total value (6,895,223 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, CHARLES.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 3,374,140 | $48.6M | 48.9% | — |
| 2 | MORGAN STANLEY | 2,014,788 | $29.0M | 29.2% | ADD +71.3% |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 391,461 | $5.6M | 5.7% | NEW |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 333,086 | $4.8M | 4.8% | TRIM -57.9% |
| 5 | BANK OF AMERICA CORP /DE/ | 300,609 | $4.3M | 4.4% | TRIM -27.6% |
| 6 | FMR LLC | 266,095 | $3.8M | 3.9% | ADD +36.3% |
| 7 | TWO SIGMA INVESTMENTS, LP | 129,941 | $1.9M | 1.9% | TRIM -25.8% |
| 8 | WELLS FARGO & COMPANY/MN | 85,103 | $1.2M | 1.2% | ADD +77.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | TRIM | 415,306 | 300,609 | -27.6% | $4.3M | 2025-Q4 |
| FMR LLC | ADD | 195,190 | 266,095 | +36.3% | $3.8M | 2025-Q4 |
| MORGAN STANLEY | ADD | 994,756 | 1,704,268 | +71.3% | $16.4M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 572,499 | 415,306 | -27.5% | $4.0M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 735,200 | 309,486 | -57.9% | $3.0M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 207,951 | 154,286 | -25.8% | $1.5M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 41,377 | 73,519 | +77.7% | $709.5K | 2025-Q3 |
| MORGAN STANLEY | TRIM | 2,066,895 | 994,756 | -51.9% | $8.2M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 296,800 | 735,200 | +147.7% | $6.0M | 2025-Q2 |
| UBS Group AG | ADD | 199,569 | 307,874 | +54.3% | $2.5M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 326,708 | 207,951 | -36.3% | $1.7M | 2025-Q2 |
| CITADEL ADVISORS LLC | ADD | 662,208 | 1,073,236 | +62.1% | $7.7M | 2025-Q1 |
| FMR LLC | DOUBLED | 1,556 | 168,384 | +10721.6% | $1.2M | 2025-Q1 |
| NORGES BANK | EXIT | 449,400 | 0 | -100.0% | $0.00 | 2025-Q1 |
| MORGAN STANLEY | ADD | 1,349,876 | 2,003,311 | +48.4% | $15.5M | 2024-Q4 |
| CITADEL ADVISORS LLC | DOUBLED | 238,331 | 662,208 | +177.9% | $5.1M | 2024-Q4 |
| NORGES BANK | NEW | — | 449,400 | — | $3.5M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 271,300 | — | $2.1M | 2024-Q4 |
| UBS Group AG | ADD | 111,485 | 193,303 | +73.4% | $1.5M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 36,152 | 48,437 | +34.0% | $374.4K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 417,739 | — | $4.4M | 2024-Q3 |
11 unique insiders with 2 transactions. Net insider value: -$221.7K ($0.00 bought, $221.7K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 29, 2026 | Tasse Daniel | Director | A | 46,600 | $0.00 | $0.00 |
| May 29, 2026 | STUMP DAVID C | Director | A | 46,600 | $0.00 | $0.00 |
| May 29, 2026 | STUMP DAVID C | Director | A | 9,807 | $0.00 | $0.00 |
| May 29, 2026 | Zachary Jennifer | Director | A | 46,600 | $0.00 | $0.00 |
| May 29, 2026 | Zachary Jennifer | Director | A | 9,807 | $0.00 | $0.00 |
| May 29, 2026 | Tasse Daniel | Director | A | 9,807 | $0.00 | $0.00 |
| May 29, 2026 | Mills Kenneth T. | Director | A | 9,807 | $0.00 | $0.00 |
| May 29, 2026 | MIGAUSKY GEORGE V | Director | A | 46,600 | $0.00 | $0.00 |
| May 29, 2026 | KARABELAS ARGERIS N | Director | A | 9,807 | $0.00 | $0.00 |
| May 29, 2026 | Fox Allan M. | Director | A | 46,600 | $0.00 | $0.00 |
| May 29, 2026 | Bennett Jean | Director | A | 9,807 | $0.00 | $0.00 |
| May 29, 2026 | Glucksmann Alexandra | Director | A | 9,807 | $0.00 | $0.00 |
| May 29, 2026 | Glucksmann Alexandra | Director | A | 46,600 | $0.00 | $0.00 |
| May 29, 2026 | Mills Kenneth T. | Director | A | 46,600 | $0.00 | $0.00 |
| May 29, 2026 | MIGAUSKY GEORGE V | Director | A | 9,807 | $0.00 | $0.00 |
| May 29, 2026 | Fox Allan M. | Director | A | 9,807 | $0.00 | $0.00 |
| May 29, 2026 | KARABELAS ARGERIS N | Director | A | 46,600 | $0.00 | $0.00 |
| May 29, 2026 | Bennett Jean | Director | A | 46,600 | $0.00 | $0.00 |
| May 11, 2026 | PAKOLA STEVE | Chief Medical Officer | SELL | 15,309 | $11.02 | $168.7K |
| Mar 10, 2026 | PAKOLA STEVE | Chief Medical Officer | SELL | 5,124 | $10.35 | $53.0K |
| Feb 1, 2026 | Christmas Patrick J. | Chief Strategy & Legal Officer | F | 4,700 | $11.16 | $52.5K |
| Feb 1, 2026 | PAKOLA STEVE | Chief Medical Officer | F | 5,267 | $11.16 | $58.8K |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 2 mixed, 1 neutral. Avg impact: 5.3/10.
NEUTRAL
8-K
3/10
REGENXBIO reported results of its 2026 Annual Meeting held May 29, 2026, where shareholders elected
Jun 3, 2026
MIXED
8-K
7/10
REGENXBIO reported Q1 2026 results with a net loss of $90.1M ($1.72/share) vs. net income of $6.1M a
May 14, 2026
MIXED
8-K
6/10
REGENXBIO reported financial results for Q4 and full year 2025, showing increased revenue driven by
Mar 5, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (89% buy). Based on 19 analysts: 6 strong buy, 11 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$24.18 mean target
+297.7% upside
Strong Buy (1.55)
$10.00 Low
$50.00 High
| Metric | Value |
|---|---|
| Current Price | $6.08 |
| Target Low | $10.00 |
| Target Mean | $24.18 |
| Target Median | $19.00 |
| Target High | $50.00 |
| # Analysts | 11 |
| Recommendation | Strong Buy (1.55) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.34 | $0.10 | $0.73 | 124.9% | +244.3% | 1↑ 2↓ | $0.1B | 457.3% | 6 |
| Next Q 2026-09-30 |
$-1.48 | $-1.63 | $-1.39 | -23.5% | -33.0% | 1↑ 3↓ | $0.0B | -20.4% | 6 |
| Current FY 2026-12-31 |
$-2.85 | $-4.91 | $1.61 | 24.2% | -42.5% | 1↑ 0↓ | $0.2B | 38.5% | 8 |
| Next FY 2027-12-31 |
$-2.52 | $-4.58 | $-0.24 | 11.5% | -14.8% | 1↑ 0↓ | $0.3B | 15.4% | 6 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.344 | |
| 7d ago | $0.100 | +0.244 |
| 30d ago | $0.100 | +0.244 |
| 60d ago | $0.100 | +0.244 |
| 90d ago | $-0.443 | +0.787 |
8 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 5, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 15, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| May 15, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Mar 9, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 6, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Feb 10, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 10, 2026 | Goldman Sachs | MAINTAIN | Neutral | Neutral |
| Feb 10, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Feb 10, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Jan 29, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Dec 19, 2025 | Stifel | MAINTAIN | Buy | Buy |
| Dec 15, 2025 | Leerink Partners | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 11 | 2 | 0 | 0 | 89% | |
| May 1, 2026 | 6 | 11 | 2 | 0 | 0 | 89% | |
| Apr 1, 2026 | 6 | 11 | 2 | 0 | 0 | 89% | |
| Mar 1, 2026 | 6 | 11 | 2 | 0 | 0 | 89% | |
| Feb 1, 2026 | 6 | 11 | 2 | 0 | 0 | 89% | |
| Jan 1, 2026 | 6 | 11 | 2 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 5, 2026
short_volume
Short Volume: RGNX — 59.6% short (0.4M / 0.7M)
Short: 388,925 | Exempt: 7,720 | TRF Vol: 652,401 | Short Ratio: 59.6% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
short_volume
Short Volume: RGNX — 71.6% short (0.4M / 0.5M)
Short: 358,163 | Exempt: 50 | TRF Vol: 500,166 | Short Ratio: 71.6% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: RGNX — 60.4% short (0.4M / 0.6M)
Short: 386,586 | Exempt: 20 | TRF Vol: 640,486 | Short Ratio: 60.4% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: RGNX — 64.4% short (0.4M / 0.7M)
Short: 437,024 | Exempt: 10,392 | TRF Vol: 679,121 | Short Ratio: 64.4% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: RGNX — 63.5% short (0.8M / 1.2M)
Short: 750,539 | Exempt: 218 | TRF Vol: 1,182,280 | Short Ratio: 63.5% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: RGNX — 64.6% short (1.3M / 2.0M)
Short: 1,271,313 | Exempt: 127,554 | TRF Vol: 1,969,044 | Short Ratio: 64.6% | Off-exchange volume (dark pool + OTC)
May 14, 2026
earnings_calendar
RGNX Q1 2026 Earnings After Market Close — 2026-05-14
May 14, 2026
short_volume
Short Volume: RGNX — 63.6% short (2.6M / 4.1M)
Short: 2,639,126 | Exempt: 212,527 | TRF Vol: 4,148,005 | Short Ratio: 63.6% | Off-exchange volume (dark pool + OTC)
May 6, 2026
earnings_calendar
RGNX Q1 2026 Earnings After Market Close — 2026-05-06
Mar 5, 2026
earnings_calendar
RGNX Q4 2025 Earnings After Market Close — 2026-03-05
Mar 3, 2026
earnings_calendar
RGNX Q4 2025 Earnings After Market Close — 2026-03-03
Feb 8, 2026
fda_pdufa
PDUFA: RGNX — Clemidsogene lanparvovec in MPS II — 2026-02-08
FDA target action date 2026-02-08 for RGNX (REGENXBIO Inc.). Drug: Clemidsogene lanparvovec. Indication: MPS II. PDUFA target action date for clemidso